Equities

Profile data is unavailable for this security.

About the company

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.

  • Revenue in EUR (TTM)37.12bn
  • Net income in EUR5.57bn
  • Incorporated--
  • Employees118.20k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301
  • Fax+49 2 143066328
  • Websitehttps://www.bayer.de/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Merck KGaA14.80bn1.90bn12.62bn54.76k22.302.853.390.85294.384.4734.0535.150.41351.935.01279,803.305.355.107.066.6764.0467.7612.9511.780.6187.570.41899.152.026.5359.6135.6222.608.02
UCB SA4.57bn872.00m14.98bn7.48k16.632.429.393.284.634.6424.2731.880.45691.955.47610,992.308.933.6011.134.6773.5470.6919.549.570.919212.840.219260.549.245.5238.4926.52-1.111.55
Shionogi & Co Ltd2.64bn903.53m18.98bn5.12k20.753.6817.947.18363.73363.731,064.552,052.700.47241.495.7766,542,580.0016.2110.9718.0612.6382.6975.1734.3122.095.06--0.019929.601.704.0329.7910.29-4.3814.32
Otsuka Holdings Co Ltd9.85bn908.80m22.49bn32.82k24.151.6216.022.28215.15215.152,334.953,216.280.50302.773.4138,669,100.004.75--5.82--65.63--9.44--1.78--0.131--3.71--21.53------
Alexion Pharmaceuticals, Inc.3.43bn220.49m23.17bn2.53k106.922.8935.556.761.110.667517.5041.100.28470.96534.841,549,505.001.834.631.985.0389.2290.116.4414.912.74--0.2590.0015.1525.6422.5813.9374.88--
Astellas Pharma Inc10.15bn1.45bn25.57bn16.62k17.722.4913.132.5293.9093.90658.51667.790.69141.854.1078,693,990.009.869.1612.5611.7877.9074.6714.2612.611.56265.720.043942.11-0.86525.78-24.7012.24-12.056.72
Takeda Pharmaceutical Co Ltd13.73bn1.09bn26.48bn27.23k24.061.5510.781.93178.40178.402,253.172,764.080.40922.073.8164,991,740.003.251.674.052.1972.6270.377.944.011.045.220.3154207.482.222.6062.594.692.700.00
Chugai Pharmaceutical Co Ltd4.45bn666.30m30.75bn7.37k45.185.24--6.92156.72156.721,045.901,350.490.67061.543.3777,725,720.0010.137.7911.759.2154.1652.3815.1112.213.561,137.860.000350.008.636.6835.689.5723.289.16
Bayer AG37.12bn5.57bn58.37bn118.20k10.531.166.891.575.946.1940.4753.880.36011.563.62371,869.405.425.156.546.7662.3557.6815.058.881.047.960.465258.250.206-2.50-13.206.224.178.06
Data as of Nov 19 2018. Currency figures normalised to Bayer AG's reporting currency: Euro EUR
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.